[Mechanism of the development of akinesia in Parkinson's disease --with reference to L-threo-DOPS therapy].
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003342:Corpus Striatum / Q000032:analysis; D004298:Dopamine / Q000032:analysis; D004299:Dopamine beta-Hydroxylase / Q000378:metabolism; D015103:Droxidopa / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009068:Movement; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D009626:Terminology as Topic
D000978:Antiparkinson Agents; D007980:Levodopa; D004299:Dopamine beta-Hydroxylase; D015103:Droxidopa; D004298:Dopamine